Clinical Trial

BR101 in Patients With Relapsed/Refractory Multiple Myeloma

Name: BR101 in Patients With Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07537049)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is an open-label, single-arm, dose-escalation and dose-expansion clinical trial designed to evaluate the maximum tolerated dose, safety, pharmacokinetic profile following administration of BR101 injection, and preliminary efficacy in subjects with relapsed or refractory multiple myeloma.

Trial Details

NCT Number	NCT07537049
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences Collaborators: Byterna Therapeutics Ltd.
Conditions	Multiple Myeloma (MM)
Enrollment	10 participants
Start Date	2026-04-30
Primary Completion	2027-04-30 (estimated)
Study Completion	2029-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-17